PTC Therapeutics

Recent news

• Rating change
  BofA Securities Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Announces Target Price $95
  Market Newswire · 2026/7/15
• Rating change
  Cantor Fitzgerald Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $130
  Market Newswire · 2026/7/16
• Rating change
  Cantor Fitzgerald Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $130
  Market Newswire · 2026/8/13
• Rating change
  Goldman Sachs Maintains PTC Therapeutics(PTCT.US) With Sell Rating, Raises Target Price to $70
  Market Newswire · 2026/7/31
• Rating change
  Wells Fargo Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $109
  Market Newswire · 2026/8/13
• Wells Fargo Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $109
  Market Newswire · 2026/9/2
• Cantor Fitzgerald Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $137
  Market Newswire · 2026/9/22
• Rating change
  RBC Capital Maintains PTC Therapeutics(PTCT.US) With Hold Rating, Raises Target Price to $85
  Market Newswire · 2026/7/27
• Rating change
  Morgan Stanley Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Cuts Target Price to $93
  Market Newswire · 2026/7/23
• PTC Therapeutics, Inc.: To Assume Certain Specified Liabilities of Sangamo PTCT
  Dow Jones · 2026/8/29
• Rating change
  A Quick Look at Today's Ratings for PTC Therapeutics(PTCT.US), With a Forecast Between $90 to $106
  Market Newswire · 2026/7/31
• Rating change
  BofA Securities Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $96
  Market Newswire · 2026/8/13
• Rating change
  Barclays Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $122
  Market Newswire · 2026/8/14
• Rating change
  Wells Fargo Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $106
  Market Newswire · 2026/7/31
• TD Cowen Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $90
  Market Newswire · 2026/8/31
• Rating change
  Barclays Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $120
  Market Newswire · 2026/8/4
• PTC Therapeutics, Inc.: Upfront Payment of $111 Million, Plus Up to an Additional $100 Million in Contingent Milestone Payments PTCT
  Dow Jones · 2026/8/29
• Rating change
  Wells Fargo Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $93
  Market Newswire · 2026/7/21
• Rating change
  Analysts Offer Insights on Healthcare Companies: Tempus AI, Inc. Class A (TEM), Doximity (DOCS) and PTC Therapeutics (PTCT)
  TipRanks · 2026/7/21
• Rating change
  Morgan Stanley Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $104
  Market Newswire · 2026/7/31

Headlines are aggregated automatically and are not independently verified or edited by our team.